Can methotrexate be used in an adult with generalized pustular psoriasis who has Cushingoid changes from long‑term oral corticosteroids and cannot take retinoids?

Can Methotrexate Be Used in Generalized Pustular Psoriasis with Cushingoid Changes?

Yes, methotrexate can be used in this case and is specifically indicated for generalized pustular psoriasis (GPP), particularly when retinoids are contraindicated. 1, 2, 3

Rationale for Methotrexate in This Clinical Scenario

Strong Evidence Supporting Use in GPP

• Methotrexate is especially effective for acute generalized pustular psoriasis, with reported efficacy rates of 76.2% in a large Japanese multicenter study 2 and is specifically recommended for this severe variant 3

• The American Academy of Dermatology/National Psoriasis Foundation guidelines provide a Grade A recommendation for methotrexate in moderate to severe psoriasis in adults, which encompasses GPP 1

• Methotrexate is particularly useful as a short-term option to gain control of unstable psoriasis such as pustular psoriasis before transitioning to other therapies, or as long-term maintenance 3

Why This Patient Is a Candidate

• The patient cannot take retinoids, which are typically first-line for GPP (84.1% efficacy) 2, making methotrexate a logical alternative

• The Cushingoid changes from long-term corticosteroids actually support transitioning to methotrexate, as it can allow for gradual steroid reduction in patients who respond 4

• The patient needs to be weaned off corticosteroids given the complications, and methotrexate provides a steroid-sparing alternative 1

Critical Safety Considerations Before Initiating

Mandatory Baseline Assessments

Before starting methotrexate, you must document 1, 4:

• Complete blood count (CBC) - to assess for baseline bone marrow function
• Renal function (creatinine clearance) - methotrexate is renally cleared and toxicity increases with impairment 4
• Liver function tests and hepatitis B/C serology - baseline liver assessment is essential 1
• Noninvasive liver fibrosis assessment (such as vibration-controlled transient elastography or hepatic-specific serology) - baseline liver biopsy is NOT recommended 1
• Pregnancy test if applicable - methotrexate is absolutely contraindicated in pregnancy 1

Key Risk Factors to Evaluate

Assess for hepatotoxicity risk factors 1, 4:

• Alcohol use (>1 drink/day for women, >2 drinks/day for men)
• Obesity and diabetes (common with Cushingoid changes)
• Chronic liver disease (hepatitis B/C)
• History of other hepatotoxic drug exposure

If multiple risk factors are present, consider alternative therapy first, but if methotrexate is chosen, annual GI/hepatology referral or elastography is required 1

Dosing and Administration Protocol

Starting Regimen

• Begin with 7.5-25 mg weekly (NOT daily - this is a common fatal error) 1, 5
• Consider a test dose, especially given the need to assess tolerance 1
• Administer as a single weekly dose or divided into 3 doses over 24 hours 1
• Route can be oral or subcutaneous (subcutaneous may have better bioavailability) 1

Essential Concurrent Therapy

• Mandatory folic acid or folinic acid supplementation to reduce GI and hepatic adverse effects 1
• Avoid large doses of folate that may reduce methotrexate efficacy 1

Monitoring Requirements

Frequent Laboratory Surveillance

• Every 3-6 months: CBC, renal function, liver function tests (assuming no abnormalities) 1
• If abnormal elevations occur: repeat in 2-4 weeks 1
• If persistently elevated: GI referral required 1
• Annual monitoring if risk factors present: noninvasive hepatic serology regardless of cumulative dose 1

Critical Warning Signs Requiring Immediate Action

Stop methotrexate immediately if 4:

• Significant drop in blood counts (WBC <3000/mm³, platelets <100,000/mm³)
• Vomiting, diarrhea, or stomatitis causing dehydration 4
• Pulmonary symptoms (consider Pneumocystis carinii pneumonia) 4
• Persistent liver function abnormalities 1

Common Pitfalls to Avoid

Fatal Dosing Errors

• Never prescribe methotrexate daily - it is a weekly medication 5
• A recent case report documented death from daily intramuscular administration when the weekly prescription was misunderstood 5
• Provide clear written instructions and a monitoring booklet 1

Drug Interactions

• Avoid concomitant NSAIDs and salicylates when possible, as they increase toxicity risk 1, 6
• Sulfonamides are particularly dangerous in combination with methotrexate 6
• Review all medications for potential interactions 4

Elderly Patient Considerations

• Bone marrow suppression, thrombocytopenia, and pneumonitis increase with age 4
• Monitor more closely for early signs of hepatic, bone marrow, and renal toxicity 4

Alternative Considerations

While methotrexate is appropriate here, be aware that 7, 8:

• IL-36 pathway inhibitors (spesolimab) are now approved specifically for GPP and may be considered if methotrexate fails 9, 8
• Cyclosporine has 71.2% efficacy in GPP and may be an alternative if methotrexate is not tolerated 2
• IL-17 and IL-23 inhibitors have emerging evidence in GPP 7, 8

In this specific case with Cushingoid changes and retinoid contraindication, methotrexate is a reasonable and evidence-based choice, provided proper screening, dosing verification, and monitoring protocols are strictly followed. 1, 2, 3